Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 30, 2026, 9:32 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 265–288 of 1,891 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Prostate Cancer Patients Clear all
Terminated Phase 2 Interventional

CT-2584 in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Previous Therapy

NCT00004026
View directory record Official record
Conditions
Prostate Cancer
Interventions
CT-2584, chemotherapy
Drug
Lead sponsor
CTI BioPharma
Industry
Eligibility
18 Years to 120 Years · Male only
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2005
U.S. locations
7
States / cities
Los Angeles, California • San Francisco, California • New Orleans, Louisiana + 4 more
Source: ClinicalTrials.gov public record
Updated Oct 19, 2020 · Synced Oct 30, 2026, 9:32 PM EDT
Recruiting Not applicable Interventional

Patient Decision-making About Precision Oncology in Veterans With Advanced Prostate Cancer

NCT05396872
View directory record Official record
Conditions
Prostate Cancer, Advanced Prostate Carcinoma
Interventions
Participant Surveys, Mobile app
Other
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Mar 9, 2026 · Synced Oct 30, 2026, 9:32 PM EDT
Completed Not applicable Interventional

Sipuleucel-T and Low-protein Diet in Patients With Metastatic Castrate-resistant Prostate Cancer

NCT03329742
View directory record Official record
Conditions
Prostate Cancer Recurrent
Interventions
Low protein diet, Control protein diet
Other
Lead sponsor
Indiana University
Other
Eligibility
18 Years and older · Male only
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
2
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Mar 29, 2021 · Synced Oct 30, 2026, 9:32 PM EDT
Completed Not applicable Interventional

Pomegranate Juice in Treating Patients With Recurrent Prostate Cancer

NCT00060086
View directory record Official record
Conditions
Prostate Cancer
Interventions
pomegranate juice
Dietary Supplement
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years and older · Male only
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2021
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jun 4, 2021 · Synced Oct 30, 2026, 9:32 PM EDT
Completed Phase 2 Interventional Results available

Zometa on Bone Mineral Density in Prostate Cancer Patients Undergoing Androgen Ablation Therapy

NCT00582556
View directory record Official record
Conditions
Prostate Cancer
Interventions
Zometa
Drug
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older · Male only
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2013
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Nov 26, 2019 · Synced Oct 30, 2026, 9:32 PM EDT
Completed Phase 2 Interventional

Continuation Trial Evaluating the Tolerability and Activity of FK228 in Patients That Completed Prior Study With FK228

NCT00106301
View directory record Official record
Conditions
Carcinoma, Renal Cell, Prostatic Neoplasms
Interventions
FK228 (romidepsin)
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
4
States / cities
Duarte, California • Gainesville, Florida • Chicago, Illinois + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 18, 2019 · Synced Oct 30, 2026, 9:32 PM EDT
Completed Not applicable Interventional

Caloric Restriction Before Surgery in Treating Patients With Endometrial, Prostate, or Breast Cancer

NCT02983279
View directory record Official record
Conditions
Breast Carcinoma, Endometrial Carcinoma, Prostate Carcinosarcoma
Interventions
Dietary Intervention, Counseling, Therapeutic
Dietary Supplement · Other · Procedure
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Other
Eligibility
18 Years and older
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 29, 2025 · Synced Oct 30, 2026, 9:32 PM EDT
Active, not recruiting Phase 2 Interventional

Trametinib in Treating Patients With Progressive Metastatic Hormone-Resistant Prostate Cancer

NCT02881242
View directory record Official record
Conditions
Hormone-Resistant Prostate Cancer, Metastatic Prostate Carcinoma, Recurrent Prostate Carcinoma, Stage IV Prostate Cancer
Interventions
Laboratory Biomarker Analysis, Quality-of-Life Assessment, Trametinib
Other · Drug
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years and older · Male only
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated May 1, 2023 · Synced Oct 30, 2026, 9:32 PM EDT
Withdrawn Phase 1 Interventional

Autologous T Cells Lentivirally Transduced to Express L1CAM-Specific Chimeric Antigen Receptors in Treating Patients With Locally Advanced and Unresectable or Metastatic Small Cell Neuroendocrine Prostate Cancer

NCT06094842
View directory record Official record
Conditions
Prostate Carcinoma, Prostate Small Cell Neuroendocrine Carcinoma, Stage III Prostate Cancer AJCC v8, Stage IV Prostate Cancer AJCC v8
Interventions
Bendamustine, Biopsy, Biospecimen Collection, Bone Scan, Bridge Therapy, Computed Tomography, Cyclophosphamide, Echocardiography, Fludarabine, Leukapheresis, Multigated Acquisition Scan, T-cell Receptor-engineered T-cells, X-Ray Imaging
Drug · Procedure · Biological
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
18 Years and older · Male only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Apr 1, 2025 · Synced Oct 30, 2026, 9:32 PM EDT
Completed Phase 2 Interventional

A Phase II Trial of Adjuvant Docetaxel in Patients At High Risk of Relapse Following Prostatectomy

NCT00069888
View directory record Official record
Conditions
Prostate Cancer
Interventions
Docetaxel
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older · Male only
Enrollment
83 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2007
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated Jun 8, 2011 · Synced Oct 30, 2026, 9:32 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional

FOR46 in Combination With Enzalutamide in Patients With Metastatic Castration Resistant Prostate Cancer

NCT05011188
View directory record Official record
Conditions
Metastatic Castration-resistant Prostate Cancer, Prostate Cancer
Interventions
FOR46, Enzalutamide, Pegfilgrastim, Blood Samples
Biological · Drug · Procedure
Lead sponsor
Rahul Aggarwal
Other
Eligibility
18 Years and older · Male only
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Sep 17, 2026 · Synced Oct 30, 2026, 9:32 PM EDT
Completed Phase 2 Interventional Results available

Neoadjuvant Bevacizumab Plus Docetaxel in High Risk Patients With Prostate Cancer Undergoing Radical Prostatectomy

NCT00321646
View directory record Official record
Conditions
Prostate Cancer, Adenocarcinoma of the Prostate
Interventions
Bevacizumab, Docetaxel
Drug
Lead sponsor
Mary-Ellen Taplin, MD
Other
Eligibility
18 Years and older · Male only
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2012
U.S. locations
3
States / cities
Boston, Massachusetts • Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated May 16, 2016 · Synced Oct 30, 2026, 9:32 PM EDT
Terminated Phase 1 Interventional

Vaccine Therapy in Treating Patients With Metastatic Prostate Cancer

NCT00010127
View directory record Official record
Conditions
Prostate Cancer
Interventions
therapeutic autologous dendritic cells
Biological
Lead sponsor
Duke University
Other
Eligibility
18 Years and older · Male only
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2003
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 21, 2013 · Synced Oct 30, 2026, 9:32 PM EDT
Completed Phase 2 Interventional Results available

Open Label Study to Assess Efficacy and Safety of Olaparib in Confirmed Genetic BRCA1 or BRCA2 Mutation Pats

NCT01078662
View directory record Official record
Conditions
Ovarian, Breast, Prostate, Pancreatic, Advanced Tumours
Interventions
olaparib
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
298 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2024
U.S. locations
2
States / cities
West Hollywood, California • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 13, 2025 · Synced Oct 30, 2026, 9:32 PM EDT
Completed Phase 2 Interventional

Comparison Study of MDX-010 (CTLA-4) Alone and Combined With Docetaxel in the Treatment of Patients With Hormone Refractory Prostate Cancer

NCT00050596
View directory record Official record
Conditions
Prostate Cancer
Interventions
MDX-010 / MDX-010 + Docetaxel
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older · Male only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2004
U.S. locations
11
States / cities
Tucson, Arizona • Long Beach, California • San Diego, California + 7 more
Source: ClinicalTrials.gov public record
Updated Jun 27, 2011 · Synced Oct 30, 2026, 9:32 PM EDT
Suspended Not applicable Interventional

Adaptive Radiation Therapy for Men With Intermediate- or High-Risk Prostate Cancer

NCT07219303
View directory record Official record
Conditions
Prostate Cancer (Adenocarcinoma)
Interventions
adaptive stereotactic body radiation therapy (SBRT) with a SIB
Radiation
Lead sponsor
Fox Chase Cancer Center
Other
Eligibility
18 Years and older · Male only
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2033
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 29, 2026 · Synced Oct 30, 2026, 9:32 PM EDT
Completed Phase 3 Interventional Results available

Interstitial Brachytherapy With or Without External-Beam Radiation Therapy in Treating Patients With Prostate Cancer

NCT00063882
View directory record Official record
Conditions
Prostate Cancer
Interventions
Brachytherapy (100/110), Brachytherapy (125/145), External Beam Radiation Therapy
Radiation
Lead sponsor
Radiation Therapy Oncology Group
Network
Eligibility
18 Years to 120 Years · Male only
Enrollment
588 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2022
U.S. locations
168
States / cities
Phoenix, Arizona • Auburn, California • Berkeley, California + 122 more
Source: ClinicalTrials.gov public record
Updated Mar 5, 2026 · Synced Oct 30, 2026, 9:32 PM EDT
Completed Phase 1Phase 2 Interventional Results available

ADXS31-142 Alone and in Combination With Pembrolizumab (MK-3475) in Participants With Previously Treated Metastatic Castration-Resistant Prostate Cancer (mCRPC)

NCT02325557
View directory record Official record
Conditions
Cancer, Prostate Cancer
Interventions
ADXS31-142, Pembrolizumab
Drug
Lead sponsor
Advaxis, Inc.
Industry
Eligibility
18 Years and older · Male only
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
8
States / cities
San Francisco, California • Aurora, Colorado • Rockville, Maryland + 4 more
Source: ClinicalTrials.gov public record
Updated Apr 2, 2024 · Synced Oct 30, 2026, 9:32 PM EDT
Completed Phase 2 Interventional Results available

A Parallel Group Comparison of the Efficacy and Safety of Degarelix at Two Different Dosing Regimens in Patients With Prostate Cancer

NCT00116779
View directory record Official record
Conditions
Prostate Cancer
Interventions
Degarelix
Drug
Lead sponsor
Ferring Pharmaceuticals
Industry
Eligibility
18 Years and older · Male only
Enrollment
127 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
26
States / cities
Homewood, Alabama • Anchorage, Alaska • Anaheim, California + 23 more
Source: ClinicalTrials.gov public record
Updated Dec 19, 2011 · Synced Oct 30, 2026, 9:32 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional

A Phase 1-2 Study of ST101 in Patients With Advanced Solid Tumors

NCT04478279
View directory record Official record
Conditions
Glioblastoma, Melanoma Stage IV, Breast Cancer, Prostate Cancer, Glioblastoma Multiforme, GBM, Brain Cancer, Metastatic Breast Cancer, Metastatic Melanoma, Metastatic Prostate Cancer, Melanoma Recurrent, Prostate Cancer Metastatic, Recurrent Glioblastoma, Newly Diagnosed Glioblastoma
Interventions
ST101, Temozolomide, Radiation
Drug · Radiation
Lead sponsor
Sapience Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
125 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
7
States / cities
San Francisco, California • Denver, Colorado • Warrenville, Illinois + 4 more
Source: ClinicalTrials.gov public record
Updated Feb 9, 2026 · Synced Oct 30, 2026, 9:32 PM EDT
Terminated Not applicable Interventional Results available

Calcium-41 (41Ca) Chloride Aqueous Solution in Diagnosing Patients With Prostate Cancer and Bone Metastasis

NCT00918645
View directory record Official record
Conditions
Metastatic Cancer, Prostate Cancer
Interventions
41 Ca
Drug
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years and older · Male only
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
1
States / cities
Livermore, California
Source: ClinicalTrials.gov public record
Updated Dec 22, 2017 · Synced Oct 30, 2026, 9:32 PM EDT
Active, not recruiting Not applicable Interventional

Focal Salvage HDR Brachytherapy for Locally Recurrent Prostate Cancer in Patients Treated With Prior Radiotherapy

NCT03312972
View directory record Official record
Conditions
Locally Recurrent Prostate Cancer
Interventions
HDR Brachytherapy
Radiation
Lead sponsor
Loyola University
Other
Eligibility
18 Years and older · Male only
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2026
U.S. locations
2
States / cities
Maywood, Illinois • Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Sep 24, 2025 · Synced Oct 30, 2026, 9:32 PM EDT
Active, not recruiting Not applicable Interventional

Stereotactic Body Radiation Therapy in Treating Patients With Localized High-Risk Prostate Cancer

NCT02296229
View directory record Official record
Conditions
Adenocarcinoma of the Prostate, Stage III Prostate Cancer
Interventions
stereotactic body radiation therapy, quality-of-life assessment, laboratory biomarker analysis, androgen deprivation therapy
Radiation · Other · Drug
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years and older · Male only
Enrollment
220 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2027
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Feb 25, 2026 · Synced Oct 30, 2026, 9:32 PM EDT
Completed Phase 2 Interventional Results available

Tecemotide (L-BLP25) in Prostate Cancer

NCT01496131
View directory record Official record
Conditions
Prostate Cancer
Interventions
Radiation therapy, Goserelin, Cyclophosphamide, Tecemotide (L-BLP25)
Radiation · Drug
Lead sponsor
EMD Serono
Industry
Eligibility
18 Years and older · Male only
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
1
States / cities
Rockland, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 9, 2018 · Synced Oct 30, 2026, 9:32 PM EDT